ENSC vs PRGO vs HLN vs COLL

For growth investors, Ensysce Biosciences, Inc.

(ENSC) is the stronger pick with 133. 5% revenue growth year-over-year, versus -4. 0% for Haleon plc (HLN). Haleon plc (HLN) offers the better valuation at 18. 7x trailing P/E (21. 6x forward), making it the more compelling value choice. Analysts rate Haleon plc (HLN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Haleon plc (HLN) is the cheapest at 18.

7x versus Collegium Pharmaceutical, Inc. at 21. 8x. On forward P/E, Collegium Pharmaceutical, Inc. is actually cheaper at 5. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Collegium Pharmaceutical, Inc. wins at 0. 28x versus Haleon plc's 2. 56x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Collegium Pharmaceutical, Inc.

(COLL) delivered a total return of +71. 9%, compared to -100. 0% for Ensysce Biosciences, Inc. (ENSC). Over 10 years, the gap is even starker: COLL returned +143. 2% versus ENSC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Haleon plc (HLN) is the lower-risk stock at 0.

03β versus Perrigo Company plc's 1. 21β — meaning PRGO is approximately 4132% more volatile than HLN relative to the S&P 500. On balance sheet safety, Ensysce Biosciences, Inc. (ENSC) carries a lower debt/equity ratio of 9% versus 3% for Collegium Pharmaceutical, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ensysce Biosciences, Inc.

(ENSC) is pulling ahead at 133. 5% versus -4. 0% for Haleon plc (HLN). On earnings-per-share growth, the picture is similar: Haleon plc grew EPS 12. 5% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, COLL leads at 18. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Haleon plc (HLN) is the more profitable company, earning 15.

1% net margin versus -153. 3% for Ensysce Biosciences, Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: COLL leads at 24. 0% versus -129. 2% for ENSC. At the gross margin level — before operating expenses — HLN leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Collegium Pharmaceutical, Inc. (COLL) is the more undervalued stock at a PEG of 0. 28x versus Haleon plc's 2. 56x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Collegium Pharmaceutical, Inc. (COLL) trades at 5. 1x forward P/E versus 21. 6x for Haleon plc — 16. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.

In this comparison, ENSC (100.

0% yield), PRGO (9. 8% yield), HLN (2. 0% yield) pay a dividend. COLL does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Haleon plc (HLN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

03), 2. 0% yield). Both have compounded well over 10 years (HLN: +29. 0%, PRGO: -77. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ENSC is a small-cap high-growth stock; PRGO is a small-cap income-oriented stock; HLN is a mid-cap quality compounder stock; COLL is a small-cap high-growth stock. ENSC, PRGO, HLN pay a dividend while COLL does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.